Sandoz to launch third Neulasta biosimilar

Sandoz has received FDA approval for Ziextenzo pegfilgrastim-bmez and plans to price it at a monthly wholesale acquisition cost of $3,925, a 37% discount to the WAC for Amgen neutropenia drug Neulasta.

The entry of Ziextenzo sets the stage for competition among three biosimilars for the U.S. market for Neulasta pegfilgrastim. Sandoz, a unit of Novartis AG (NYSE:NVS; SIX:NOVN), plans to launch the drug this year. ...